Varsha M K N Sai, Thiagarajan R, Manikandan R, Dhanasekaran G
Department of Bioengineering, School of Chemical & Biotechnology, SASTRA University, Thanjavur, India.
Department of Bioengineering, School of Chemical & Biotechnology, SASTRA University, Thanjavur, India.
Nutrition. 2015 Jan;31(1):214-22. doi: 10.1016/j.nut.2014.05.012. Epub 2014 Jun 20.
The aim of this study was to understand the mechanism of action of vitamin K1 against streptozotocin (STZ)-induced diabetes.
Male Wistar rats were administered 35 mg/kg STZ and after 3 d were treated with vitamin K1 (5 mg/kg, twice a week) for 3 months. Blood glucose was monitored twice a month. At the end of the study, animals were sacrificed and pancreas dissected out and analyzed for free radicals, antioxidants, metabolic enzymes related to glucose, membrane ATPases, histopathological evaluation, and expression of nuclear factor (NF)-κB and inducible nitric oxide synthase (iNOS). Glycated hemoglobin, plasma insulin, and islet area were determined at the end of the study.
Treatment of STZ-induced type 1 diabetic rats with vitamin K1 reduced oxidative stress, enhanced antioxidants, and inhibited aldose reductase in pancreas. Vitamin K1 administration rescued endocrine pancreas from STZ-induced cell death, resulting in enhanced insulin secretion and normal blood glucose and glycosylated hemoglobin levels. Histologic analyses also showed the antidiabetic potential of vitamin K1. Measure of pancreatic islet area showed an increase in the islet area upon vitamin K1 treatment when compared with the STZ-administered group, suggesting the possibility of regeneration. To understand the mechanism involved in vitamin K1 mediated changes, we performed immunohistochemical analyses for NF-κB and iNOS enzyme. Vitamin K1 was shown to suppress NF-κB activation and iNOS expression in the islets upon administration of STZ.
This work shows, to our knowledge for the first time, the mechanism of action of vitamin K1 against type 1 diabetes and the possible therapeutic use of this vitamin in stimulating islet cell proliferation/regeneration.
本研究旨在了解维生素K1抗链脲佐菌素(STZ)诱导糖尿病的作用机制。
给雄性Wistar大鼠注射35mg/kg STZ,3天后用维生素K1(5mg/kg,每周两次)治疗3个月。每月监测两次血糖。在研究结束时,处死动物,取出胰腺并分析自由基、抗氧化剂、与葡萄糖相关的代谢酶、膜ATP酶、组织病理学评估以及核因子(NF)-κB和诱导型一氧化氮合酶(iNOS)的表达。在研究结束时测定糖化血红蛋白、血浆胰岛素和胰岛面积。
用维生素K1治疗STZ诱导的1型糖尿病大鼠可降低氧化应激,增强抗氧化剂,并抑制胰腺中的醛糖还原酶。给予维生素K1可使内分泌胰腺免受STZ诱导的细胞死亡,从而增强胰岛素分泌并使血糖和糖化血红蛋白水平正常化。组织学分析也显示了维生素K1的抗糖尿病潜力。胰腺胰岛面积测量显示,与给予STZ的组相比,维生素K1治疗后胰岛面积增加,提示有再生的可能性。为了解维生素K1介导变化的机制,我们对NF-κB和iNOS酶进行了免疫组织化学分析。结果显示,给予STZ后,维生素K1可抑制胰岛中NF-κB的激活和iNOS的表达。
据我们所知,本研究首次揭示了维生素K1抗1型糖尿病的作用机制以及该维生素在刺激胰岛细胞增殖/再生方面可能的治疗用途。